All of the 4 patients with CASPR2 antibody-associated encephalitis received first-line immunotherapy: IVMP pulse and/or IVIG, and only 1 patient(case 1) were added with second-line immunotherapy. This evidence concerns the gene CNTNAP2 and viral encephalitis.